Thymosin Beta-4 Fragment (Ac-SDKP)
Also known as: N-Acetyl-Ser-Asp-Lys-Pro, Acetyl-N-Ser-Asp-Lys-Pro, Goralatide
Overview
Ac-SDKP (N-acetyl-seryl-aspartyl-lysyl-proline) is a naturally occurring tetrapeptide released from thymosin beta-4 by prolyl oligopeptidase and ACE2 cleavage. It is a powerful regulator of hematopoietic stem cell proliferation, inhibiting entry of pluripotent hematopoietic stem cells into the S-phase of the cell cycle—protecting them from cycle-dependent cytotoxic damage during chemotherapy. Ac-SDKP also exerts significant antifibrotic effects in the heart, kidneys, and lungs, and is hydrolyzed by ACE (angiotensin-converting enzyme), explaining why ACE inhibitors elevate plasma Ac-SDKP levels.
Mechanism of Action
Ac-SDKP acts through multiple mechanisms: (1) Hematopoietic stem cell cycle arrest—inhibits G0-S transition via BMP4/SMAD pathway suppression, protecting stem cells from S-phase cytotoxic chemotherapy; (2) Antifibrotic—suppresses TGF-β1-induced myofibroblast differentiation and collagen synthesis in cardiac and renal fibroblasts; (3) Anti-inflammatory—reduces macrophage activation and TNF-α/IL-6 production; (4) Angiogenic—promotes endothelial cell migration and tube formation. Its ACE-mediated hydrolysis links it to the renin-angiotensin system.
Potential Benefits
- Bone marrow stem cell protection during chemotherapy
- Cardiac and renal antifibrotic activity
- Anti-inflammatory via macrophage and cytokine modulation
- Elevates naturally with ACE inhibitor use
- Potential in heart failure, kidney disease, and lung fibrosis
Dosage Protocols
The following reflects doses used in published research studies. This is not medical advice. Consult a qualified healthcare professional.
| Beginner | Not a consumer peptide — research only |
| Intermediate | N/A |
| Advanced | N/A |
| Cycle Duration | Preclinical cardiac/fibrosis models: weeks |
Ac-Ser-Asp-Lys-Pro tetrapeptide. Endogenous hematopoiesis and antifibrotic regulator — released from Thymosin Beta-4.
Use our Reconstitution Calculator to determine exact syringe units for your protocol.
Routes of Administration
Subcutaneous or IV (research) High but very short half-life
Rapidly degraded by ACE — often studied with ACE inhibitor co-administration.
Read our full Routes of Administration Guide for detailed comparison of all delivery methods.
Stacking Protocols
Popular research stacks involving Thymosin Beta-4 Fragment (Ac-SDKP):
Explore our complete Peptide Stacking Guide for more combinations and safety considerations.
Reconstitution
| Storage | Refrigerate at 2-8°C after reconstitution. Do not freeze reconstituted solution. |
|---|
Typical vial sizes: 1-5 mg (research). Add bac water slowly down the side of the vial, swirl gently — do not shake. Use insulin syringe for precise dosing.
Need exact syringe measurements?
Amino Acid Sequence
Ac-Ser-Asp-Lys-Pro
Side Effects & Safety
- Well-tolerated in clinical studies
- Potential excess stem cell cycle suppression at very high doses
Safety & Contraindications
This information is for educational purposes only. Consult a qualified healthcare provider before using any peptide.
Pregnancy / Lactation
Bleeding Disorders
Active Skin Infection at Injection Site
Pharmacokinetics
| Half-Life | ~4-5 minutes (degraded by ACE) |
|---|---|
| Storage | Store lyophilized peptide at -20°C (long-term) or 2-8°C (short-term, under 30 days). Reconstituted: refrigerate at 2-8°C and use within 28-30 days. Protect from light. Do not freeze reconstituted solution. |
Synergistic Compounds
The following compounds have been studied alongside Thymosin Beta-4 Fragment (Ac-SDKP) for potential complementary or synergistic effects:
Learn More
References & Further Reading
Latest News & Research
View all articles →
FDA Staff Reviewers Say ‘No’ to 7 Compounded Peptides Ahead of July PCAC Vote
FDA staff reviewers urged against adding seven popular peptides to the 503A bulks list ahead of the July PCAC meeting, citing weak human data and safety uncertainty.
FDA reviewers urge ‘no’ on BPC-157, TB-500, MOTS-c ahead of July 2026 compounding vote
FDA reviewers’ June 29 briefings recommend against listing seven popular peptides for 503A compounding, citing limited human data and immunogenicity risk.
Medicare Starts Paying for Obesity Drugs Today — Bridge Program Opens $50 Access for Millions
Medicare's new $50 Bridge program covering Wegovy, Zepbound, Foundayo, and oral Wegovy for obesity launched July 1 — the first Medicare weight-loss benefit.
FDA staff urges caution on compounded peptides ahead of July advisory meeting
Ahead of the July 23–24 Pharmacy Compounding Advisory Committee meeting, FDA staff briefings recommend against listing seven popular peptides for compounding.